|Bid||15.21 x 800|
|Ask||15.32 x 800|
|Day's Range||15.21 - 15.31|
|52 Week Range||9.91 - 24.07|
|PE Ratio (TTM)||104.86|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.67|
Group Inc. have reached a preliminary agreement to resolve legal disputes. Under the terms of the tentative pact announced Monday, American Renal Associates and UnitedHealth agreed to enter into a three-year network agreement as of Aug. 1 that would, among other things, give those covered by UnitedHealthcare medical plans in-network access to American Renal Associates’s dialysis clinics. American Renal Associates would pay UnitedHealth $32 million as part of the agreement.
American Renal Associates Holdings, Inc. (ARA) and UnitedHealthcare, a UnitedHealth Group company (UNH) today announced that they have executed a binding Settlement Term Sheet (the “Agreement”) and will be negotiating terms of a definitive settlement by August 1, 2018. Under the terms of the Agreement, ARA will pay $32 million and will follow certain procedures and share information with UnitedHealthcare. In conjunction with the Agreement, ARA and UnitedHealthcare will enter into a three-year network agreement, effective August 1, 2018, that will provide UnitedHealthcare plan participants with more cost effective, in-network access to all of ARA’s dialysis clinics in 26 states and the District of Columbia.
NEW YORK, June 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accuray ...
This analysis is intended to introduce important early concepts to people who are starting to invest and want a simplistic look at the return on American Renal Associates Holdings IncRead More...
Aramus SA. (WSE:ARA) trades with a trailing P/E of 3x, which is lower than the industry average of 9.7x. While ARA might seem like an attractive stock to buy, itRead More...
LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Heska Corp. (NASDAQ: HSKA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=HSKA as the Company's latest news hit the wire. On May 15, 2018, the Company announced that it has signed a licensing agreement with MBio Diagnostics, Inc. ("MBio") for the development of new products and solutions aimed at the animal health market. Active-Investors.com is currently working on the research report for American Renal Associates Holdings, Inc. (NYSE: ARA), which also belongs to the Healthcare sector as the Company Heska.
NEW YORK, May 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Paycom ...
The Beverly, Massachusetts-based company said it had a loss of 1 cent per share. Earnings, adjusted for non-recurring costs, came to 11 cents per share. The results beat Wall Street expectations. The average ...
American Renal Associates Holdings, Inc. , a leading provider of outpatient dialysis services, today announced financial and operating results for the first quarter ended March 31, 2018.
American Renal Associates Holdings, Inc. , a leading provider of dialysis services, today announced it will participate at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, NV.
American Renal Associates Holdings, Inc. (ARA), a leading provider of dialysis services, announced today that it will release its first quarter 2018 financial results after the market close on Tuesday, May 8, 2018, to be followed by a conference call on Wednesday, May 9, 2018 at 9:00 a.m. (Eastern Time). The conference call can be accessed live over the phone by dialing (877) 407-8029, or for international callers (201) 689-8029. A replay will be available one hour after the call and can be accessed by dialing (877) 660-6853, or for international callers (201) 612-7415.
American Renal Associates Holdings, Inc. , a leading provider of outpatient dialysis services, is pleased to announce that the Company has received preliminary approval of the settlement of a stockholder derivative action brought by Plaintiff Stephen Bushansky, and pending in the United States District Court for the District of Massachusetts (case number No.
With an ROE of 24.26%, Aramus SA. (WSE:ARA) outpaced its own industry which delivered a less exciting 12.98% over the past year. While the impressive ratio tells us that ARARead More...
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
American Renal Associates Holdings, Inc. , a provider of outpatient dialysis services, today announced that it has withdrawn the offering of shares of its common stock that was announced on Monday, March 26, 2018.
American Renal Associates Holdings, Inc. , a provider of outpatient dialysis services, today announced the launch of an underwritten public offering of 5,000,000 shares of its common stock by certain stockholders , including Centerbridge Capital Partners, L.P.
Investors are always looking for growth in small-cap stocks like Aramus SA. (WSE:ARA), with a market cap of ZŁ6.51M. However, an important fact which most ignore is: how financially healthyRead More...
American Renal Associates Holdings (ARA) operates its dialysis clinics mainly through a joint venture model. Most of its clinics are maintained as separate joint ventures in which American Renal Holdings has the controlling interest, and its nephrologist partners and other joint venture partners have a noncontrolling interest.
Its nephrologist partners also generate awareness and recognition about American Renal Associates Holdings within the broader nephrology community and provide recommendations of potential new nephrologist partners. The company intends to leverage its joint venture model to continue to develop de novo clinics in new as well as existing markets in the United States. At the end of December 2017, American Renal Associates Holdings had 177 clinics developed as de novo clinics in its portfolio.
American Renal Associates Holdings (ARA) is the largest dialysis services provider in the United States with an exclusive focus on joint venture partnerships with physicians. Of the three analysts covering American Renal Associate Holdings in March 2018, two analysts have given the stock a “strong buy” rating and one analyst has given it a “buy” rating. Of the four analysts covering Civitas Solutions (CIVI) in March 2018, two analysts have given the stock a “strong buy” rating, and two analysts have given it a “buy” rating.
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / American Renal Associates Holdings, Inc. (NYSE: ARA ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018, at 9:00 ...
On a per-share basis, the Beverly, Massachusetts-based company said it had net income of 5 cents. Earnings, adjusted for non-recurring costs, came to 18 cents per share. The results topped Wall Street ...